OUTCOME MEASURES
infection, death, pneumonia, ’
ADVERSE REACTIONS, PNEUMONIA, ASYMPTOMATIC COVID-19, INFECTION, SECONDARY, COMPLICATIONS
The trial had two primary outcomes: incidence of ‘symptomatic COVID-19’ and incidence of ‘severe COVID-19’ during the 6 months after randomisation. Complete definitions of primary and secondary outcomes are available in the Secondary outcomes included: time to COVID-19 onset; number of COVID-19 episodes; number of days with symptoms, absence from work or confined to bed; complications (including pneumonia, need for oxygen, hospitalisation, admission to critical care, mechanical ventilation, death); and asymptomatic infection, all within 6 months of randomisation. Vaccine-related adverse reactions were also monitored.